Starling Oncology, Inc. Deferred State and Local Income Tax Expense (Benefit)
Starling Oncology, Inc. (DFPH) reported Deferred State and Local Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-03-12
- Starling Oncology, Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was $0.00.
- Starling Oncology, Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $0.00.
- Starling Oncology, Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$78.00K.
- Starling Oncology, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$128.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2023-12-31 | -$78.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | -$128.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | -$338.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | -$425.00K 10-K · filed 2022-03-11 |